• Uzma Nabi
  • A H Nagi
  • Waqas Sami


Background: The objective of this study was to assess the relationship of histological type, grade andstage of colorectal carcinoma with proliferative activity as measured by Ki-67 LI. It was a descriptivestudy and conducted at the Department of Pathology, University of Health Sciences, Lahore. Methods:Ki-67 is a protein associated with cell proliferation and is expressed in all the phases of cell cycle exceptG0. In the present study, Ki-67 expression in 50 patients with colorectal adenocarcinomas was observedusing immunohistochemistry with monoclonal antibody MIB-1. Results: Ki-67 LI was high in well andmoderately differentiated adenocarcinomas (mean Ki-67 LI 392.50± 56.58 and 342.24±96.84respectively) as compared to poorly differentiated adenocarcinomas (mean Ki-67 LI 250.00±113.46). Ki-67 LI was high in non mucinous adenocarcinomas than mucin secreting and signet ring celladenocarcinomas (mean Ki-67 393.93±55.91 vs 220.00±49.72 and 200.00±79.05 respectively). As regardthe Dukes’ staging, Ki-67 LI was high in colorectal carcinomas in Dukes’ stage B than tumours in Dukes’stage C (Mean Ki-67 LI 360.13±90.03 vs 241.66±101.31 respectively). Conclusion: The proliferativeactivity as measured by Ki-67 antibody is related to histological type, grade and stage.Keywords: Colorectal carcinoma, Grade, Proliferation index, Immunohistochemistry, Ki-67


Bisgaard LM. Young age colorectal cancer and identification

of hereditary non-polyposis colorectal cancer cohorts. Br J

Surg 2007;94:1055–6.

J Ayub Med Coll Abbottabad 2008;20(4)

Reza MM, Blasco AJ, Andradas E, Cantero R, Mayol J.

Systematic review of laparoscopic versus open surgery for

colorectal cancer. Br J Surg 2006;93:921–8.

Skjelbred F C, Sæbø M, Hjartaker A, Grotmol T, Hansteen LI,

Tveit MK, et al. Meat, vegetables and genetic polymorphisms

and the risk of colorectal carcinoma and adenomas. BMJ

Cancer 2007;7:228–34.

Soreide K, Janssen MAE, Soiland H, Korner.H, Baak APJ.

Microsatellite instability in colorectal cancer. Br J Surg


Conlin A, Smith G, Carey A. F, Wolf R. C, Steele CJR. The

prognostic significance of K-ras, p53, and APC mutations in

colorectal carcinoma. Gut 2005;54:1283–86.

Leslie A, Carrey FA, Pratt NR, Steele RJC. The colorectal

adenoma_carcinoma sequence. Br J Surg 2002;89:845–60.

Rosai J. Gastrointestinal tract In: Ackerman’s surgical

pathology. 9th ed. St. Louis: Mosby, 2004;p. 750–858.

Raraty MG, Winstanley JH. Variation in the staging of

colorectal carcinomas: a survey of current practice. Ann R Coll

Surg Engl 1998;80:188–91.

Gordon PH, Nivatvongs S. editors. Principles and practice of

surgery for the colon, rectum and anus. Missouri: Karen

Berger, 1992;p.503–20.

Oshima FTC, Iriya K, Forones MN. Ki-67 as a prognostic

marker in colorectal cancer but not in gastric cancer. Neoplasm


Urruticocechea A, Smith EI, Dowsett M. Proliferation Marker

Ki-67 in Early Breast Cancer. J Clin Oncol 2005;23:7212–20.

Bancroft J, Anderson G. Tissue Processing and Microtomy

including Frozen. In: Bancroft JD, Gamble M, editors. Theory

and practice of Histological techniques.5th ed. New York:

Churchill Livingstone, 2002; p. 85–107.

Key M. Immunohistochemical Staining Methods, 4th ed.

Avaiable from:


Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of

bcl-2 Oncoprotein Immunohistochemical Expression with

Proliferation Index and Histopathologic Parameters in

Colorectal Neoplasia. AppI Immunohistochem Mol Morphol


Valera. V, Yokoyama. N, Walter. B, Okamoto. H, Suda.T and

Hatakeyama. K. Clinical significance of Ki-67 proliferation

index in disease progression and prognosis of patients with

resected colorectal carcinoma.Br J Surg 2005;92:1002–7.

Ishida H, Sadahiro S, Suzuki T, Ishikawa K, Kamijo A, Tajima

T et al. Proliferative, infiltrative and metastatic activities in

colorectal tumours assessed by MIB-1 antibody. Oncology


Lanza G Jr, Cavazzini L, Borghi L, Ferretti S ,Buccoliero F and

Rubbini M. Immunohistochemical assessment of growth

fraction in colorectal adenocarcinomas with monoclonal

antibody Ki-67. Relation to clinical and pathological variables.

Path Res Prac 1990;186:608–18.

Georgescu VC, Saftoiu A, Georgescu CC, Ciurea R, Ciurea T.

Correlation of Proliferation Markers, p53 expression and

Histological Findings in Colorectal carcinomas. J gastroenterol

and liver diseases 2007;16:125–9.

Jansson A, Sun XF. Ki-67 expression in relation to

clinicopathological variables and prognosis in colorectal

adenocarcinomas.APMIS 1997;9:730–4.

Shepherd AN, Richman IP, England J. Ki-67 derived

proliferative activity in colorectal adenocarcinoma with

prognostic correlations. J Pathol 1988;155:213–9.

Kyzer S, Gordon HP. Determination of proliferative activity in

colorectal carcinoma using monoclonal antibody Ki-67. Dis

Colon Rectum 1997;40:322–5.

Sahin AA, Ro JY, Brown RW, Ordonez NG, Cleary KR, el

Naggar AK, Assessment of Ki-67 derived tumour

proliferative activity in colorectal adenocarcinomas. Mod

Pathol 1994;1:17–22.

Petrowsky H, Sturm I, Graubitz O, Kooby AD, Staib-Sebler E,

Gog C et al. Relevance of Ki-67 antigen expression and K-ras

mutation in colorectal liver metastases. E J S O 2001;27:80–7.

.Michael-Robinson MJ, Reid EL, Puride MD, BiemerHuttmann EA, Walsh DM, Pandeeya N, et al. Proliferation

,Apoptosis and Survival in High Level Microsatellite

Instability Sporadic Colorectal Cancer. Clinical Cancer

Research 2001;7:2347–56.



Most read articles by the same author(s)